Umeclidinium

Umeclidinium

Drug monograph · NCLEX study reference
Trade names	Incruse
Therapeutic class	Bronchodilator
Pharmacologic class	Long-acting anticholinergic (LAMA)
Onset / peak / duration	Duration 24 hours.
Half-life / level	Long; no routine level.
Routes	Inhaled
High-alert (ISMP)	No
Black box warning	None
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use if needed.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

Umeclidinium (brand name Incruse) — Bronchodilator; Long-acting anticholinergic (LAMA).

Identification

• Therapeutic class: Bronchodilator.
• Pharmacologic class: Long-acting anticholinergic (LAMA).

Pharmacology

• Mechanism of action: Sustained muscarinic blockade.
• Onset / peak / duration: Duration 24 hours.
• Half-life / therapeutic level: Long; no routine level.

Clinical use

• Indications: COPD maintenance.
• Usual dose, route, frequency: Inhaled once daily.
• Maximum dose / adjustments: Once daily.

Safety

• Contraindications: Hypersensitivity; caution with glaucoma and urinary retention.
• Black box warning: None.
• Interactions: Other anticholinergics.
• Pregnancy / lactation: Use if needed.
• High-alert: No.

Adverse effects

• Common side effects: Dry mouth, cough, upper respiratory symptoms.
• Serious effects to report: Acute glaucoma, urinary retention, paradoxical bronchospasm.
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Respiratory status, glaucoma and prostate history.
• Interventions during therapy: Maintenance only.
• Monitor: Respiratory status.
• Evaluation / expected outcome: Improved breathing.

Patient teaching

• Patient teaching: Daily controller, not a rescue.
• Notify provider if: Eye or urinary symptoms.
• Administration tips: Once daily inhaled.